Compare PUBM & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PUBM | CERS |
|---|---|---|
| Founded | 2006 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | EDP Services |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.6M | 276.0M |
| IPO Year | 2020 | 1996 |
| Metric | PUBM | CERS |
|---|---|---|
| Price | $8.13 | $1.67 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $18.44 | N/A |
| AVG Volume (30 Days) | 813.8K | ★ 1.8M |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $282,926,000.00 | $51,326,000.00 |
| Revenue This Year | $3.33 | $20.00 |
| Revenue Next Year | $8.29 | $9.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $6.15 | $1.12 |
| 52 Week High | $13.26 | $2.96 |
| Indicator | PUBM | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 56.39 | 30.59 |
| Support Level | $7.97 | $1.37 |
| Resistance Level | $9.12 | $1.72 |
| Average True Range (ATR) | 0.46 | 0.16 |
| MACD | 0.08 | -0.08 |
| Stochastic Oscillator | 63.56 | 5.19 |
PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.